|
 |
VireadThis page contains recent news articles, when available, and an overview of Viread but does not offer medical advice. You should contact your physician with regard to any health issues or concerns....å?Œæ–¹éƒ½å°†å°±å?„自的Viread?在亚洲地区的销售情况支付对方专利使用费。å?Œæ–¹çš„å…±å?Œç›®æ ‡æ˜¯æ‰©å¤§å??议的覆盖范围，包括日本å?Šå…¶ä»–原æ?¥æœªèƒ½è¦†ç›–的国家。 ... 凤凰网 Study Identifies Viread And Emtriva As The Preferred Initial Treatment For HIV ... - Dec 10, 2009 A recent study finds Viread (tenofovir) and Emtriva (emtricitabine) are more effective nucleoside reverse transcriptase inhibitors (NRTIs) than Ziagen ... The AIDS Beacon (blog) AIDS Prevention Gel Fails In Trial - Dec 15, 2009 ...drugs like tenofovir, dapivirine and maraviroc are beginning to be tested, including a formulation using Gilead Sciences Inc.'s drug Viread, or tenofovir. Visit Bulgaria Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015 ... - Dec 15, 2009 Truvada and Isentress are the HIV brands that will Drive the Market and Competition 9.3 Key Product Analysis 9.3.1 Truvada 9.3.2 Atripla 9.3.3 Viread ... IT News Online 抗乙è‚?æ–°è?¯Viread将在ä¸å›½ä¸Šå¸‚ - Dec 16, 2009 ...本报讯（记者æ?¨ç?ºï¼‰11月24日，Gilead与GSK宣布一项在ä¸å›½ä¸Žè?”å?ˆå¼€å?‘和上市Vireadçš„å??议，该è?¯åœ¨äºšæ´²å›½å®¶ç”¨äºŽæ²»ç–—æˆ?人慢性乙è‚?病毒感染（HBV）。GSKä¿?ç•™Viread在ä¸å›½çš„ ... 腾讯网 美英制è?¯å…¬å?¸å°†åœ¨å?Žå¼€å±•ä¹™è‚?æ–°è?¯ä¸´åºŠç ”究 - Dec 10, 2009 ...马å¸?æ?©ç§°ï¼Œè¯¥è?¯çš„化å¦å??是“富马酸替诺ç¦?韦二å?¡å‘‹é…¯(Viread)â€?å±žäºŽæ–°åž‹æ ¸è‹·é…¸ç±»é€†è½¬å½•é…¶æŠ‘åˆ¶å‰‚ï¼Œèƒ½å®ƒé€šè¿‡å¹²æ‰°ä¹™è‚?病毒DNAè?šå?ˆé…¶åŠŸèƒ½ï¼ŒæŠ‘制乙è‚?病毒的å¤?制，é™?低血清å?Šè‚? ... 凤凰网 FDA Approves HIV Drug Viread for Chronic Hepatitis B in Adults - Aug 12, 2008 By Miranda Hitti. Aug. 12, 2008 -- The FDA has approved the HIV drug Viread for the treatment of chronic hepatitis B in adults. ... WebMD US patent office rejects Gilead Viread patents - Jan 23, 2008 By Deena Beasley. LOS ANGELES, Jan 23 (Reuters) - US patent officials have rejected four patents on Gilead Sciences Inc's (GILD.O) AIDS drug Viread, ... Reuters Analysis: Gilead may get boost from Viread - Jun 7, 2007 By STEVE MITCHELL, UPI Senior Medical Correspondent. WASHINGTON, June 7 (UPI) -- Gilead's HIV drug Viread may get a boost from a phase 3 trial showing it's ... United Press International Gilead studies of Viread for hepatitis B treatment achieve primary … - Nov 2, 2007 NEW YORK (Thomson Financial) - Gilead Sciences Inc. Friday said two Phase III studies evaluating the efficacy and safety of Viread for the treatment of ... Forbes BW50: Gilead's Big Growth Spurt - Apr 25, 2005 He decided to stick with Viread -- and even predicted that it would be 10 times safer. ... Just six years later, Viread is Gilead's top-selling drug, ... BusinessWeek Gilead Signs New Viread Pact - Aug 14, 2006 Gilead Sciences (GILD Quote) agreed to give three Indian drugmakers licenses to produce and sell a generic version of its HIV drug Viread in 95 low-income ... TheStreet.com - TheStreet.com (subscription) Gilead's Viread wins EU backing for hepatitis B - Mar 20, 2008 LONDON, March 20 (Reuters) - US biotechnology company Gilead Sciences Inc (GILD.O) said on Thursday a European committee had recommended approving its ... Reuters Gilead asks US, EU to approve Viread for hep B - Oct 11, 2007 LOS ANGELES, Oct 11 (Reuters) - Gilead Sciences Inc (GILD.O) said on Thursday it has asked regulators in the United States and Europe to approve its AIDS ... Reuters Gilead: US patent office confirms second of four Viread patents - Jun 2, 2008 SAN FRANCISCO (Thomson Financial) - Gilead Sciences Inc. said Monday the US Patent & Trademark Office has completed the second of four reexamination ... Forbes Maker Won't Tout 'Promising' HIV Drugs - Mar 30, 2006 Truvada is a combination of two of the company's drugs, Viread and Emtriva, ... Viread, which the FDA approved in 2001, became one of the most popular AIDS ... FOXNews New HIV Regimen Outperforms Gold Standard - Jan 18, 2006 Note that this study suggests that the regimen of Viread (tenofovir DF), ... The new kid on the block is a combination of Viread (tenofovir DF), ... CNN Gilead says US upholds one Viread patent - May 20, 2008 LOS ANGELES, May 20 (Reuters) - Gilead Sciences Inc (GILD.O) said on Tuesday that US patent officials have upheld one of the four challenged patents ... Reuters FDA Backs AIDS Pill to Be Taken Once a Day - Jul 13, 2006 One of its big sellers is Truvada, a once-a-day combination of Viread, also known as tenofovir, and Emtriva, also known as emtricitabine. ... New York Times Gilead's Viread does well against hepatitis in second test - Jun 25, 2007 Gilead Sciences Inc. said Monday that its HIV treatment Viread did well in a second late stage clinical trial where it is being tested as a treatment for ... Bizjournals.com Gilead Beats Targets | Robert Steyer News | Print Financial &... - Apr 19, 2005 Truvada combines Emtriva and Viread in a single tablet. Sales of Hepsera, a drug for people with chronic hepatitis B virus, jumped to $42.7 million from ... TheStreet.com - TheStreet.com (subscription) Gilead posts 53% surge in quarterly profit - Jul 19, 2007 Viread sales stood at $154.9 million vs. the $153.8 million consensus forecast and first-quarter result of $160.7 million. Emtriva saw second-quarter sales ... MarketWatch Gilead aims to speed AIDS drugs to poor: Effort is response to... - Aug 12, 2006 The drug makers could export generic Viread to developing countries. The company's efforts are cutting the cost of Viread and Truvada to less than $1 per ... Free with registration - News & Observer - AccessMyLibrary.com Gilead says US upholds one Viread patent - May 21, 2008 LOS ANGELES, May 20 (Reuters) - Gilead Sciences Inc (GILD.O: Quote, Profile, Research) said on Tuesday that US patent officials have upheld one of the four ... Reuters India Gilead Walks Past Estimates | Biotech/Pharmaceuticals | Financial … - Jul 19, 2005 Among drugs, Gilead said Viread sales were $209.1 million in the second quarter, up 6% from a year ago, while sales of Truvada were $123.1 million, ... TheStreet.com - TheStreet.com (subscription) Decade of delay afflicts drug to prevent AIDS - May 18, 2006 A year's supply of Viread costs about $5300 and Truvada about $8800. ... If Viread is ever used as a preventive in poor countries, Gilead says it will ... Pittsburgh Post-Gazette - Pittsburgh Post Gazette United States 9th Circuit Court of Appeals Reports - IN RE GILEAD … - Aug 11, 2008 One of the company's commercial products is Viread, an antiretroviral agent used ... Sales of Viread amounted to about 65% of Gilead's total revenues at all ... Pay-Per-View - United States 9th Circuit Court of... - Loislaw Gilead Shares Face Limited Upside - Nov 15, 2005 Gilead expects to file for approval of new triple combination formula featuring its Truvada (Viread/Emtriva) and Bristol-Myers Squibb's (nyse: BMY - news ... Forbes Gilead Sciences profit surges 55% - Apr 18, 2007 Sales of Viread came in at $160.7 million, rising from $159.5 million in the fourth quarter but down from $191.8 million the year before and compared with a ... MarketWatch Africa: Daily HIV/Aids Report - Aug 13, 2008 Viread, which has been available in the US as an HIV/AIDS treatment since 2001, works by blocking an enzyme necessary for hepatitis B replication in liver ... AllAfrica.com Gilead Sciences posts net loss, sales jump - Oct 18, 2006 Third-quarter sales of Viread fell 10% to $170.6, while Emtriva sales fell 21% ... Wall Street had been forecasting Viread sales of $160 million and Emtriva ... MarketWatch … 48-week data from study 934 comparing Viread and Emtriva to... - Feb 3, 2005 This study was designed to compare a regimen of Viread (tenofovir disoproxil fumarate), ... Participants in one arm of the study receive Viread 300 mg, ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Mylan unit gets clearance for generic Viread - Dec 4, 2007 Mylan Inc. said its Matrix Laboratories subsidiary has received tentative clearance from the US Food and Drug Administration to market tenofovir disoproxil ... Bizjournals.com … -Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(... - Dec 15, 2006 Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of 96-week data from an ongoing clinical trial, Study 934, in the Journal of Acquired ... RedOrbit Gilead AIDS Drugs May Hold Key to Prevent Infections - Aug 4, 2008 The trials will examine the use of single daily doses of Gilead's Viread and ... Gilead sells a month's supply of Viread to US wholesalers for about $552 ... Bloomberg Atripla Makers Seek European Approval - Oct 9, 2006 The two drugs, Emtriva and Viread, are also prescribed as a once-daily combined tablet known as Truvada. Efavirenz is sold in a number of countries by Merck ... TheStreet.com - TheStreet.com (subscription) Protests may slow test of HIV drug. - Jun 15, 2005 The tension is high since experts say the drug, Viread, is the best hope among ... The federal Centers for Disease Control and Prevention has called Viread ... Free with registration - San Jose Mercury News - AccessMyLibrary.com … - De evaluerende fase III studie van Gilead inzake Viread voor de... - Jul 6, 2007 The study shows that Viread is non-inferior to the company's once-daily antiviral ... At 48 weeks, 70.8 percent of patients in the Viread arm (n=250) had a ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Data Demonstrating Significant Efficacy Of Viread(R) In Treating... - Dec 4, 2008 Gilead Sciences, Inc. (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the ... Medical News Today - Medical News Today (press release) First Quarter 2006 Earnings Release and Conference Call - Part 1. - Apr 18, 2006 This growth continues to be driven by strong sales of Truvada and Viread. ... Viread sales in the United States for the first quarter of 2006 decreased by ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Data From Two Pivotal Phase III StudiesEvaluating Viread(R) For... - Nov 5, 2007 Studies 102 and 103 compare Viread to Gilead's Hepsera® (adefovir ... Forty-eight week data show that Viread was well-tolerated by patients in both studies. ... Medical News Today - Medical News Today (press release) Netherlands Corporate News - Gilead komt met update over ontwikkeling... - Sep 8, 2005 Safety and efficacy studies using Truvada tablets or using Emtriva and Viread in combination are ongoing. Emtriva and Viread have each been studied as part ... Netherlands Corporate News - Netherlands Corporate News (persbericht) European Commission Approves Viread(R) for Chronic Hepatitis B - Apr 25, 2008 Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission has granted marketing authorisation for Viread(R) (tenofovir disoproxil ... Genetic Engineering News - Genetic Engineering News (press release) Gilead Set For Further Upside On Strong HIV Franchise - Apr 19, 2006 ..."Additional upside from Viread in hepatitis B, early-stage candidates in hepatitis C, and Phase III data from the recent investment in Corus Pharma (nyse: ... Forbes South Africa: Nod for Aids Drugs is Cost Poser for State - Apr 25, 2007 Viread and Truvada are new-generation AIDS drugs that have fewer ... Viread contains tenofovir, while Truvada combines tenofovir with emtricitabine. ... AllAfrica.com 48-Week Data Comparing Viread Versus Abacavir as Replacement for … - Feb 28, 2005 BOSTON -- Gilead Sciences (Nasdaq:GILD) today announced the presentation of preliminary 48-week data from the RAVE (Randomized Abacavir Viread Evaluation) ... $4.95 - Business Wire - ECNext Gilead lets 8 more Indian firms make generic HIV drug. - Sep 23, 2006 ..."We're hoping this will expand access to Viread as quickly as possible to ... He noted that having the Indian firms making generic Viread should help keep ... Free with registration - San Jose Mercury News - AccessMyLibrary.com Gilead HIV Drug Gets Boost From US - Nov 3, 2008 The DHHS named Gilead's Truvada, a combination of the company's HIV treatments Emtriva and Viread, the lone preferred regimen for previously untreated HIV ... TheStreet.com - TheStreet.com (subscription) Anti-AIDS blitz sees pharma firms locked in ugly battle - Sep 1, 2007 Cipla had refused Gilead's offer to sell the latter's anti-AIDS drug Viread under a licensing agreement. Cipla is also the only Indian company opposing ... Economic Times … -Year Data from Pivotal Phase III Studies Evaluating Viread(R) for... - Jan 11, 2008 Studies 102 and 103 will evaluate treatment with Viread for up to eight years ... Patients in both studies were originally randomized to receive Viread or ... FinanzNachrichten.de Gilead cuts Viread, Truvada prices to LDCs.(Gilead Sciences Inc.)(Brie... - Sep 5, 2005 US drugmaker Gilead Sciences has announced price reductions for its antiretroviral medications Viread (tenofovir disoproxil fumarate) and Truvada ... $4.95 - Pharma Marketletter - ECNext Combo drugs show promise in fighting the virus - May 23, 2006 But given the monkey study, researchers want to determine if better protection can be offered by Truvada, a combination of Viread and the second Gilead drug ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Phase III Study Evaluating Gilead's Viread for the Treatment of... - Jun 11, 2007 Gilead Sciences announced that Study 102, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread 300 mg as a potential ... FDA news - FDA news (subscription) … from PivotalPhase III Studies Evaluating Viread® for Chronic... - Mar 11, 2008 Studies 102 and 103 will evaluate treatment with Viread for up to eight years ... Patients in both studies were originally randomized to receive Viread or ... elEconomista.es Gilead Sciences at SG Cowen & Co. 25th Annual Health Care … - Mar 15, 2005 Our products such as Truvada and Viread are really best-in-class molecules. ... Truvada, Viread, and Emtriva make up our HIV franchise. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com FOSTER CITY US issues subpoena to HIV drug firm - Dec 8, 2006 In 2003, the FDA warned Gilead that its sales representatives were downplaying the risks and exaggerating the benefits of Viread. It was the second such ... San Francisco Chronicle Study Finds Viread Advantages in Black Patients - Mar 9, 2007 By Tim Horn. An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients are more likely to maintain undetectable viral loads for ... AIDSmeds.com HIV/AIDS Treatment News … -Year Data from Pivotal Phase III Studies Evaluating Viread(R) for... - Nov 1, 2008 Studies 102 and 103 will evaluate treatment with Viread for up to eight years ... Patients in both studies were originally randomized to receive Viread or ... International Business Times Analysis: Strong Q2 expected from Gilead. - Jul 20, 2006 Viread, on the other hand, is expected to experience negative growth until it ... "As such, we believe Viread may have a competitive edge over Telbivudine, ... Free with registration - UPI Health Business - AccessMyLibrary.com PROTESTS MAY SLOW TEST OF HIV DRUG - DOCTORS SEE PROMISE … - Jun 13, 2005 The tension is high since experts say the drug, Viread, is the best hope among ... The federal Centers for Disease Control and Prevention has called Viread ... $2.95 - San Jose Mercury News - NewsBank Gilead Sciences Announces Second Quarter 2008 Financial Results - Jul 17, 2008 Viread(R) (tenofovir disoproxil fumarate) sales were $150.7 million for the ... The decrease in Viread sales in the second quarter of 2008 compared to the ... Genetic Engineering News - Genetic Engineering News (press release) Gilead Boosted Partly By Currencies (GILD) - Oct 16, 2008 Antviral sales grew 39% to $1.23 billion from sales of AIDS drugs Atripla growing 77% to $427.6 million, Truvada growing 34% to $549.1 million, and Viread ... MarketWatch FDA Approves Viread® for Chronic Hepatitis B in Adults - Aug 13, 2008 FOSTER CITY, Calif. -- Gilead Sciences, Inc. announces that the US Food and Drug Administration (FDA) has granted marketing approval for Viread® (tenofovir ... Infection Control Today Once-a-day HIV drug cocktail — in one pill — wins FDA approval - Jul 16, 2006 The drugs are Bristol-Myers Squib's Sustiva and Gilead Pharmaceutical's Truvada, a combo of Viread and Emtriva. Taking the trio as a single pill makes it ... USA Today Netherlands Corporate News - Gilead Sciences meldt financiÄ—le … - Jan 30, 2006 Sales of Viread in 2005 were $778.8 million, relatively flat compared to $782.9 ... Compared to the same quarter last year, fourth quarter 2005 Viread sales ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Viread raises Hopes of HIV Prevention - Aug 13, 2006 Doors have opened to a new and potentially advantageous drug aimed at prevention of HIV, the virus that leads to AIDS. ... Money Times - The Money Times … News - Significante werkzaamheid van Viread bij chronische... - Apr 12, 2008 Studies 102 and 103 compare Viread to Hepsera among patients with compensated ... Data also indicate that at week 48, Viread was superior to Hepsera in ... Netherlands Corporate News - Netherlands Corporate News (persbericht) To launch Viread in 95 countries: Aurobindo Pharma - Sep 27, 2006 Aurobindo Pharma has tied up with Gilead Sciences to manufacture and market generic versions of Viread in 95 countries. Talking about the deal, ... Moneycontrol.com European Commission Approves Viread For Chronic Hepatitis B - Apr 28, 2008 Gilead Sciences, Inc. (NASDAQ:GILD) announced that the European Commission has granted marketing authorisation for Viread® (tenofovir disoproxil fumarate) ... Medical News Today - Medical News Today (press release) Viread With Boosted PIs Worse for Kidneys - Dec 11, 2007 People who took Viread (tenofovir) with a Norvir (ritonavir)-boosted protease inhibitor (PI) had greater declines in kidney function than people taking ... AIDSmeds.com HIV/AIDS Treatment News Caution: combination of Viread, Videx, and either Sustiva or Viramune.... - Apr 1, 2005 The combination of Viread, Videx, and either Sustiva or Viramune may cause early virologic failure in patients taking HIV needs for the first time. ... $4.95 - HIV Treatment: ALERTS! - ECNext Viread To Retail In India For $1 - Aug 20, 2006 The largest-selling HIV/AIDS drug, Viread is to be made available in India at the special price of $1 (Rs 45) per tablet, according to the manufacturer ... MedIndia … - US Food and Drug Administration keurt Viread voor volwassen... - Dec 8, 2008 Viread is now also indicated for the treatment of chronic hepatitis B in adults. ... Viread has been available in the United States as a treatment for HIV ... Netherlands Corporate News - Netherlands Corporate News (persbericht) A 'good deed' for AIDS drug hits obstacles - Jun 30, 2006 Executives at Gilead Sciences Inc. thought they were doing a good deed in 2002 when they announced a plan to provide their AIDS drug Viread to developing ... Pittsburgh Post-Gazette - Pittsburgh Post Gazette 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva … - Aug 14, 2006 TORONTO -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of 96-week data from an ongoing clinical trial (Study 934) comparing a ... Free with registration - Business Wire - AccessMyLibrary.com Drug firm accused over AIDS pledge - Feb 9, 2006 In August, Gilead slashed the price of Viread in those countries to US$208 (HK$1620) per patient annually, compared to the nearly US$5000 it costs in the ... The Standard US body denies Gilead HIV drug patent - Jan 26, 2008 US-based drug maker Gilead Sciences has found four of its US patents on Viread being turned down by the US Patent and Trademark Office (USPTO). ... Business Standard Gilead signs agreement with Indian companies to produce Viread - Aug 17, 2006 New Delhi, Aug 17 (PTI) US-based bio-pharmaceutical company Gilead Sciences today said it has signed non-exclusive licence agreement with three Indian ... Free with registration - PTI - The Press Trust of India Ltd - AccessMyLibrary.com Gilead Sciences counts on Indian pharma companies - May 14, 2007 The agreements entered into since last September cover two drugs, Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate), and allows the Indian ... Hindu Business Line |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |